Our Story

Over 6 million patients worldwide have benefited from our technology

Aerogen, the world leader in acute care aerosol drug delivery

Aerogen is synonymous with the effective treatment of respiratory illness among patient groups of all ages playing a critical role in emergency departments and intensive care units in over 75 countries worldwide.

With a strong commitment to scientific excellence, Aerogen invests heavily in research and development to evolve its pioneering product range and change the future of respiratory patient care.

History

1997

Cerus Medical founded by John Power

2000

Merger of Cerus Medical with Aerogen Inc. & IPO on NASDAQ

2003

Launch of the Aerogen Pro

2005

Acquisition of Aerogen, Inc. by Nektar Therapeutics

2007

Management buyout of Aerogen from Nektar

2008

Aerogen win IMDA Excellence Award for the Aerogen Solo

2009

Ernst & Young Entrepreneur of the Year Finalist

2011

Aerogen Integrate their ground breaking technology with MAQUET ICU ventilators

2012

Aerogen Approved for Chinese Market

2013

IMDA Medical Technology Company of the Year Award and Aerogen reach over 1 million patients

2014

Winners of the Irish Exporter of the Year

2015

Winners of the AARC Zenith Award and Aerogen reach over 3 million patients worldwide

2016

John Power named RSM European Entrepreneur of the Year. Zenith Award Recipients for 3rd time.

2017

Winners of the AARC Zenith Award for the fourth time

Our Values

We take pride in the knowledge that every day, we are working for the greater good and well-being of respiratory patients worldwide.

The Aerogen brand values underpin everything that we do and reflect Aerogen’s commitment to developing better technology to deliver better patient outcomes.

Expert

We are global leaders in high performance aerosol drug delivery. We apply our intelligence & expertise to create breakthroughs in new science for the greater good of patient care.

Mindful

We put patient’s needs at the heart of everything we do. It is our awareness and understanding of patient’s needs that allows us to take an holistic view of what’s required from Aerogen in the marketplace.

Responsive

Our high performance ethos and dedication to the task in hand drives us to seek innovative solutions to complex problems that will ultimately deliver better patient care.

Our Awards

2013

Medical Technology Company of the Year

Irish Medical Devices Association, IDA Ireland and Enterprise Ireland

2011

Silver in IMDA Excellence

Irish Medical Devices Association

2011

Finalist in Engineers Excellence Awards

Irish Engineering Awards

Sponsorships

Aerogen values the humanitarian efforts of many Irish and international charities which is why the Aerogen team is proud to give back and support these deserving charities:

Foundation Nepal

An Irish charity helping the most vulnerable in highly disadvantaged Nepalese communities to work their way out of poverty.

World Vision Ireland

One of the leading humanitarian relief organisations dedicated to addressing the causes of global poverty.

Soul of Haiti

Works to empower communities to create their own success through relationships with a community of Irish entrepreneurs. Establishing enterprise links and facilitating trade and investment in Haiti is the focus of this charity.

Society of St. Vincent de Paul

The largest voluntary organisation in Ireland today working towards a more just, caring and equal society.

CROI

A dedicated heart & stroke centre with the aim of reducing the impact of heart disease & stroke on families in the West of Ireland

John Power, CEO Aerogen, European Entrepreneur of the Year 2015/16

A Serial Entrepreneur in a technology and innovation focused career spanning over 30 years, John has held executive level positions in R&D, Operations, Sales and General Management in both the SME and MNC environment. During this period he has been a founder or co-founder of several ‘Blue Ocean’ technology start-ups the last three of these in the life-science sector.

John has led Aerogen from start-up in 1997 through a US merger, subsequent NASDAQ IPO, acquisition and MBO in 2008. Today Aerogen is recognized as a pioneer in high performance nebulisation and a global leader in ICU ventilator / Hospital based aerosol drug delivery. Its award winning products are employed in over 75 countries throughout the world helping to provide life critical interventions from the emergency department through to the NICU. Aerogen’s proprietary technology permits proteins, peptides, suspensions and solutions to be nebulised paving the way for targeted drug delivery to the lung.

Since 2008 the company has grown revenues 30%+ year on year and in recognition of its export success Aerogen was awarded the prestigious European Business Award Ruban d’Honneur in 2011 and again in 2016, where John was also named the European Entrepreneur of the Year.  Aerogen was named the Irish Exporter of the Year 2014. In 2013, 2015 & 2016 Aerogen received the highest award granted by the American Association of Respiratory Care, the Zenith Award, for ‘providing products and services that enable respiratory care physicians and therapists to achieve clinical excellence’. Also in 2013 Aerogen was voted Irish Med-Tech Company of the year.

A Chartered Engineer, John is recognized as a technology innovator and is credited with over a dozen commercialized International patents in products ranging from robotics to life-support ventilation. He holds an MBA from Oxford Brookes University and as an Adjunct Lecturer at National University of Ireland Galway (NUIG), he guest lectures on his core business interests of Innovation Strategies and Technology Entrepreneurship.

He is a founder faculty member of the NUIG Bio-Innovate program (run in conjunction with Stanford University Bio-Design), an incubator unit that promotes entrepreneurial start-up’s in medical technologies where he has actively mentored several early stage companies. In 2016 in recognition of his contribution to the development of the Irish Medical Device sector John was conferred with an Honorary Doctorate by the National University of Ireland Galway.

John is a senior member of the Board of the Irish Medical Device Association where he has represented Ireland as an Industry expert in the European Competitive Council in Brussels. He previously served as a Board member of The Irish Research Council for Science, Engineering and Technology.

John is a very active social entrepreneur in both his community where he has been chairman and long-term member of his Community Development Association and Internationally through Foundation Nepal and World Vision where he has led significant fundraising initiatives for irrigation / agricultural and local enterprise development.

 

Board of Directors

Dr Bernard Collins Chairman

As the chairman of Aerogen’s Board of Directors, Dr. Bernard Collins brings a wealth of business experience. He serves on the Board of Directors of several U.S. and Irish life-science companies. Prior to forming Lifemed, his consultancy company, Dr Collins served for 10 years as Vice President of International Operations at Boston Scientific Corporation and before this held senior executive positions in life-science companies including Baxter Corporation. His general management experience in the medical device and health care industry spans start-ups, turnarounds, leveraged buyouts and IPOs for both large and small businesses.
Dr Collins holds a BA Honors in Applied Industrial Psychology/Business from University College Cork, Ireland and an honorary Doctorate in Law from the National University of Ireland Galway. He is a recipient of the prestigious RDS Gold Medal for Industry in recognition of his extraordinary contribution to the development of the biomedical industry in Ireland.

Dr Jane E. Shaw (US)

Dr Shaw currently serves as a member of the board of Aerogen. She also serves on the Board of Lucile Packard Children’s Hospital at Stanford and Grace Cathedral, in San Francisco. She was Director of Intel from 1993 until 2012 and served as Chairman of the Board from 2009 until 2012; she served on the Boards of McKesson from 1992-2014, and Yahoo from 2014- 2017
Dr. Shaw served as Chairman and CEO of Aerogen, Inc., a specialty drug delivery company in Mountain View, California that developed drug-device combination aerosol products for patients with respiratory disorders from 1998-2005. Dr. Shaw served as President and COO of ALZA Corporation, a pharmaceutical company, from 1987 to 1994; she joined the company as a Research Scientist in 1970. She founded and led The Stable Network, a biopharmaceutical consulting company from 1994 to 1998 and has served on the Board of numerous private companies.
Dr. Shaw has received many honors and awards including the 2010 ODX Outstanding Director Award and the Outstanding Woman of Silicon Valley in 2009; she was inducted into the Bay Area Business Hall of Fame in 2016. Ms. Shaw received an honorary Doctorate of Science from Worcester Polytechnic Institute, Worcester, Massachusetts in 1992.
Dr Shaw did postdoctoral research at the Worcester Foundation for Experimental Biology in Worcester, Massachusetts from 1964-1970 after obtaining a Ph.D. in Physiology from Birmingham University, England in 1964 and a Bachelor of Science in Physiology in 1961.

Charlie Mulligan

Charlie Mulligan has been involved in the company since inception, a member of the Board since 2007 and is currently Chair of the Remuneration Committee.
His experience spans a broad range of sectors,Life Sciences, IT and Telecommunications and has been an investor in, and served on the Board of several successful businesses. He has experience in Acquisitions, Start ups, Fund Raising, Company Restructuring and Divestment activities. His business interactions have spanned both European and USA geographies.
Qualifications, in addition to 40 + years industry experience include:
HND Electronics , Belfast Technical College.
Executive Programme Diploma, Darden School of Business, University of Virginia USA.
Ford Motor Company Executive Programme, London, UK.

Charlie has served as Director on the Board of the Government owned Telecommunications Company Telecom Eireann and was CEO of Digital Equipment’s European Operations and a member of their European BOD.

Thomas Lynch

Thomas Lynch has extensive experience in life sciences and is Chair or Director of a number of biotechnology companies in the US, Ireland and UK. He started his career at KPMG and then worked at Elan Corporation plc where he led its transition from drug delivery to biotechnology. He founded a company that became Warner Chilcott plc (acquired by Allergen plc) and was Chairman and Chief Executive of Amarin Corporation plc which he successfully repositioned as a cardiovascular company. Mr Lynch was a member of the board of Icon plc from 1994 to 2016 serving as Chairman from 2012 to 2016. He continues to serve as Chair of Amarin Pharmaceuticals Ireland Ltd., its principal operating subsidiary.

Mr Lynch currently serves as Chair of the Boards of Evofem Biosciences Inc, and Profectus Biosciences Inc and as a board member of GW Pharmaceuticals plc and Aerogen Limited.

Mr Lynch is Chair of the Ireland East Hospital Group, the Mater Misericordiae University Hospital and the Dublin Academic Medical Centre. He served, at the invitation of the Minister for Health, as a member of the Expert Group on Resource Allocation in the Health Service.

Mr Lynch currently serves as Chair of Clinical Research Development Ireland (a consortium of Ireland’s medical schools) and as a member of the Advisory Board of the Institute of Human Virology, University of Maryland, Baltimore, USA.

Mr Lynch is a graduate in economics from Queen’s University Belfast and is a fellow of the Institute of Chartered Accountants in Ireland. He has received honorary doctorates from University College Dublin and Queen’s University Belfast and was appointed a knight of Saint Gregory by Pope Benedict XVI.

Steve Gannon

Steve Gannon was CFO, SVP of Finance and Treasurer at Aptalis Pharma until its acquisition by Forest Laboratories in February 2014. Previously, Mr. Gannon was the CFO of CryoCath Technologies, acquired by Medtronic in 2007. Prior to Cryocath, Mr. Gannon was Head of Finance and Administration of the Research Division of AstraZeneca Canada and CFO of Mallinckrodt’s Canadian operations. Mr. Gannon serves on the board of Xenon Pharmaceuticals (Nasdaq:XENE), as well as Laborie Medical Technologies and Engene, both private. He recently served on the board of Advanced Accelerator Applications, acquired by Novartis in January 2018.

Abhijeet Lele

Abhijeet Lele is a Managing Director at Temasek, a global investment firm based in Singapore. He previously served as Managing Director and Head of Healthcare Investing at Investor Growth Capital/Patricia Industries, leading their North American venture/growth equity and subsequently buyout efforts. Prior to joining IGC, Mr. Lele was a Managing Member of EGS Healthcare Capital Partners, a healthcare investment firm. Previously, Mr. Lele was at McKinsey & Company, and held operating positions with Lederle Laboratories, Progenics Pharmaceuticals and Clontech Laboratories. Mr. Lele has served on numerous healthcare company boards, including CryoCath Technologies, Medarex and Aptalis Pharma.